{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:51:57Z","timestamp":1792043517115,"version":"4.4.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Approved tralokinumab maintenance dosing regimens for treatment of moderate-to-severe atopic dermatitis (AD) include 300\u2005mg every 2 weeks (Q2W) and every 4 weeks (Q4W). Clinicians may consider tralokinumab Q4W for patients whose skin has become clear or almost clear at week 16 with initial Q2W dosing.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To identify predictive factors associated with maintained response after switching to tralokinumab Q4W, evaluate recapture of treatment response after relapse on Q4W, and assess treatment-emergent immunogenicity with tralokinumab Q4W.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>These post hoc analyses utilized machine learning to identify predictive factors for maintained treatment response at week 52 using data from the week 16 responder population of the phase III ECZTRA 1 and 2 trials, i.e. patients who met Investigator\u2019s Global Assessment of clear\/almost clear skin (IGA 0\/1) and\/or \u2265 75% improvement in Eczema Area and Severity Index (EASI 75) at week 16 with tralokinumab Q2W monotherapy. Top-ranked factors were then assessed individually and together to identify factors associated with a similar maintained efficacy at week 52 between patients rerandomized to tralokinumab Q2W or Q4W monotherapy at week 16. Additionally, the probability of recapturing IGA 0\/1 and\/or EASI 75 response after relapse was assessed in patients on tralokinumab Q4W transferred to the open-label arm.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The two top-ranked predictive factors for maintained response at week 52 were IGA score at week 16 (76.1%) and worst daily pruritus numeric rating scale (NRS) &amp;lt; 3 at week 16 (56.5%). Patients whose AD reached stable clinical response scores of both IGA 0\/1 and worst daily pruritus NRS &amp;lt; 3 from weeks 12\u201316 with tralokinumab Q2W similarly maintained IGA 0\/1 response at week 52 regardless of dosing regimen beyond week 16 (72.0% of patients on Q2W and 72.2% of those on Q4W). Of patients who relapsed on Q4W, 94.6% recaptured treatment response after returning to Q2W dosing. The immunogenicity potential of tralokinumab was low, and patients with positive antidrug antibodies did not show loss of efficacy or higher incidences of adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These data suggest that Q4W is an effective dosing regimen for most patients who achieved stable disease control as shown by clear\/almost clear skin and no itch to mild itch over 4 consecutive weeks on the initial regimen of tralokinumab Q2W.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljae439","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T20:35:13Z","timestamp":1733862913000},"page":"410-419","source":"Crossref","is-referenced-by-count":18,"title":["Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitis"],"prefix":"10.1093","volume":"192","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3944-252X","authenticated-orcid":false,"given":"Stephan","family":"Weidinger","sequence":"first","affiliation":[{"name":"Department of Dermatology and Allergy, University Hospital Schleswig-Holstein , Campus Kiel, Kiel ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1195-0290","authenticated-orcid":false,"given":"Anthony","family":"Bewley","sequence":"additional","affiliation":[{"name":"Barts Health NHS Trust and Queen Mary University , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9963-8319","authenticated-orcid":false,"given":"H Chih-ho","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Skin Science, University of British Columbia , Vancouver, BC ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8532-6338","authenticated-orcid":false,"given":"Juan Francisco","family":"Silvestre","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital General Universitario Dr Balmis, Instituto de Investigaci\u00f3n Sanitaria y Biom\u00e9dica de Alicante (ISABIAL) , Alicante ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5237-0463","authenticated-orcid":false,"given":"Ketty","family":"Peris","sequence":"additional","affiliation":[{"name":"Institute of Dermatology, Catholic University of the Sacred Heart , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0177-8722","authenticated-orcid":false,"given":"Andreas","family":"Wollenberg","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, Augsburg University Hospital , Augsburg ,","place":["Germany"]},{"name":"Department of Dermatology and Allergy, Ludwig Maximilian University of Munich , Munich ,","place":["Germany"]},{"name":"Comprehensive Center for Inflammation Medicine, University of L\u00fcbeck , L\u00fcbeck ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulla","family":"Ivens","sequence":"additional","affiliation":[{"name":"LEO Pharma A\/S , Ballerup ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Soehoel","sequence":"additional","affiliation":[{"name":"LEO Pharma A\/S , Ballerup ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise\u00a0Abildgaard","family":"Steffensen","sequence":"additional","affiliation":[{"name":"LEO Pharma A\/S , Ballerup ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Marie","family":"Tindberg","sequence":"additional","affiliation":[{"name":"LEO Pharma A\/S , Ballerup ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0853-0252","authenticated-orcid":false,"given":"Eric L","family":"Simpson","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Oregon Health & Science University , Portland, OR ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"2025021810015254800_ljae439-B1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet"},{"key":"2025021810015254800_ljae439-B2","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1111\/jdv.16892","article-title":"ETFAD\/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children","volume":"34","author":"Wollenberg","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025021810015254800_ljae439-B3","doi-asserted-by":"crossref","first-page":"100195","DOI":"10.1016\/j.xjidi.2023.100195","article-title":"Optimal use of Jak inhibitors and biologics for atopic dermatitis on the basis of the current evidence","volume":"3","author":"Kamata","year":"2023","journal-title":"JID Innov"},{"key":"2025021810015254800_ljae439-B4","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/jdv.18345","article-title":"European guideline (EuroGuiDerm) on atopic eczema: part I \u2013 systemic therapy","volume":"36","author":"Wollenberg","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025021810015254800_ljae439-B5","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00403-023-02566-w","article-title":"Patients\u2019 perspectives towards biologic dose reduction in psoriasis: a qualitative study","volume":"315","author":"van der Schoot","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"2025021810015254800_ljae439-B6","doi-asserted-by":"crossref","first-page":"adv00340","DOI":"10.2340\/00015555-3692","article-title":"Health economic consequences of a tightly controlled dose reduction strategy for adalimumab, etanercept and ustekinumab compared with standard psoriasis care: a cost-utility analysis of the CONDOR study","volume":"100","author":"Atalay","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"2025021810015254800_ljae439-B7","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s40265-020-01448-z","article-title":"Dose tapering of biologics in patients with psoriasis: a scoping review","volume":"81","author":"Michielsens","year":"2021","journal-title":"Drugs"},{"key":"2025021810015254800_ljae439-B8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025021810015254800_ljae439-B9","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jmb.2016.12.005","article-title":"Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13R\u03b11 and IL-13R\u03b12","volume":"429","author":"Popovic","year":"2017","journal-title":"J\u00a0Mol Biol"},{"key":"2025021810015254800_ljae439-B10","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1111\/all.15811","article-title":"Tralokinumab therapy for moderate-to-severe atopic dermatitis: clinical outcomes with targeted IL-13 inhibition","volume":"78","author":"Simpson","year":"2023","journal-title":"Allergy"},{"key":"2025021810015254800_ljae439-B11","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bjd.19573","article-title":"Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial","volume":"184","author":"Silverberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"2025021810015254800_ljae439-B12","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-\u00adcontrolled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"2025021810015254800_ljae439-B13","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s40257-023-00806-3","article-title":"Tralokinumab efficacy over 1\u2005year in adults with moderate-to-severe atopic dermatitis: pooled data from two phase III trials","volume":"24","author":"Simpson","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"2025021810015254800_ljae439-B14","doi-asserted-by":"crossref","first-page":"885672","DOI":"10.3389\/fimmu.2022.885672","article-title":"Immunogenicity of monoclonal antibodies and the potential use of HLA haplotypes to predict vulnerable patients","volume":"13","author":"Mosch","year":"2022","journal-title":"Front Immunol"},{"key":"2025021810015254800_ljae439-B15","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.jaad.2022.07.019","article-title":"Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: interim analysis of the ECZTEND open-label extension trial","volume":"87","author":"Blauvelt","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2025021810015254800_ljae439-B16","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjd.21867","article-title":"Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials","volume":"187","author":"Simpson","year":"2022","journal-title":"Br J Dermatol"},{"key":"2025021810015254800_ljae439-B17","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.jid.2018.12.018","article-title":"Atopic dermatitis is an IL-13-dominant disease with greater molecular heterogeneity compared to psoriasis","volume":"139","author":"Tsoi","year":"2019","journal-title":"J Invest Dermatol"},{"key":"2025021810015254800_ljae439-B18","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1111\/all.16108","article-title":"Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2\u2005years","volume":"79","author":"Guttman-Yassky","year":"2024","journal-title":"Allergy"},{"key":"2025021810015254800_ljae439-B19","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jamadermatol.2019.3617","article-title":"Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial","volume":"156","author":"Worm","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2025021810015254800_ljae439-B20","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/bjd\/ljad159","article-title":"Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry","volume":"189","author":"Spekhorst","year":"2023","journal-title":"Br J Dermatol"},{"key":"2025021810015254800_ljae439-B21","doi-asserted-by":"crossref","first-page":"2235041","DOI":"10.1080\/09546634.2023.2235041","article-title":"Identification of clinical predictors for dupilumab dose spacing in adults with atopic dermatitis: a real-world study","volume":"34","author":"Chiricozzi","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"2025021810015254800_ljae439-B22","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/jps.22276","article-title":"Impact of product-related factors on immunogenicity of biotherapeutics","volume":"100","author":"Singh","year":"2011","journal-title":"J Pharm Sci"},{"key":"2025021810015254800_ljae439-B23","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s40257-022-00702-2","article-title":"Tralokinumab plus topical corticosteroids as needed provides progressive and sustained efficacy in adults with moderate-to-severe atopic dermatitis over a 32-week period: an ECZTRA 3 post hoc analysis","volume":"23","author":"Silverberg","year":"2022","journal-title":"Am J Clin Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljae439\/60962035\/ljae439.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/192\/3\/410\/60962035\/ljae439.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/192\/3\/410\/60962035\/ljae439.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T10:02:04Z","timestamp":1739872924000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/192\/3\/410\/7917393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":23,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,12,5]]},"published-print":{"date-parts":[[2025,2,18]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljae439","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,12,5]]}}}